{"id":53,"date":"2026-05-01T09:36:00","date_gmt":"2026-05-01T09:36:00","guid":{"rendered":"https:\/\/bavarian-nordic.dev.grm.digital\/en\/?page_id=53"},"modified":"2026-05-26T14:55:04","modified_gmt":"2026-05-26T14:55:04","slug":"about-us","status":"publish","type":"page","link":"https:\/\/bavarian-nordic.dev.grm.digital\/fr-BE\/about-us\/","title":{"rendered":"About us"},"content":{"rendered":"\n\n\n
\n
\n \"\"\n <\/figure>\n
\n
\n
\n
\n
\n

About us<\/p>\n<\/h1>\n

Bavarian Nordic UK is protecting our tomorrow with an aim to become the UK\u2019s preferred and trusted partner for travel vaccines.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/section>\n\n \n \n\n

\n
\n

Protecting our tomorrow<\/strong><\/h2>\n
\n
\n

Combining a rich heritage in vaccine development and a supply chain spanning R&D, manufacturing and commercialisation, Bavarian Nordic UK\u00a0 is protecting our tomorrow with an aim to become the UK\u2019s preferred and trusted partner for travel vaccines.\u00a0<\/span><\/p>\n

Amidst rising travel from the UK to destinations with risk of preventable travel-related infection,1<\/sup> Bavarian Nordic UK has launched with a dedicated travel vaccines portfolio in rabies, cholera, typhoid and chikungunya.2\u20136<\/sup> And we were at the forefront of the UK government\u2019s response to mpox, providing the first approved non-replicating vaccine.7\u20139<\/sup><\/span><\/p>\n

We\u2019re standing side by side with vaccination providers, ready to support the uptake and success of travel health services.<\/span><\/p>\n<\/div>\n

\n

\"A<\/p>\n<\/div>\n<\/div>\n <\/div>\n<\/section>\n \n\n\n

\n
\n
\n
\n
\n

Building on a legacy of vaccine achievements<\/h2>\n

With pride in our achievements in vaccine development over the past 30+ years, we are focused on the future.<\/p>\n

Right now, we are working on bringing communities around the globe an even greater degree of protection from infectious disease.<\/p>\n

IMVANEX\u00ae\u25bc Smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) is currently supplied directly to the UK government for use in the mpox programme.<\/p>\n

\n

Imvanex is indicated for the active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in individuals 12 years of age and older.<\/p>\n

The use of this vaccine should be in accordance with official recommendations.<\/em><\/p>\n<\/div>\n

Vimkunya\u00ae<\/sup>\u25bc Chikungunya vaccine (recombinant, adsorbed) is the latest6<\/sup> addition to our travel portfolio and helps to protect travellers aged 12 years and older against chikungunya.6<\/sup><\/p>\n

VIMKUNYA\u00ae<\/sup> is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older.<\/p>\n

The use of this vaccine should be in accordance with official recommendations.<\/em><\/p>\n

\u00a0<\/sup><\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n
\n \n 1 <\/span>\n <\/span>\n\n

1994<\/h3>\n

Bavarian Nordic A\/S founded in Denmark<\/p>\n <\/div>\n

\n \n 2 <\/span>\n <\/span>\n\n

2019<\/h3>\n

Acquisition of Rabipur\u00ae<\/sup> (Rabies Vaccine) from GlaxoSmithKline plc10<\/sup><\/span><\/p>\n <\/div>\n

\n \n 3 <\/span>\n <\/span>\n\n

2022<\/h3>\n

EU approval of mpox vaccine, IMVANEX\u00ae<\/sup>\u25bc Smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) in adults 11<\/sup><\/span><\/p>\n <\/div>\n

\n \n 4 <\/span>\n <\/span>\n\n

2023<\/h3>\n

Acquisition of Vivotif\u00ae<\/sup> (Typhoid Vaccine, Live, Oral), Vaxchora\u00ae<\/sup> (Cholera Vaccine, Live, Oral) and pipeline assets from Emergent BioSolutions12<\/sup><\/p>\n <\/div>\n

\n \n 5 <\/span>\n <\/span>\n\n

2025<\/h3>\n

Bavarian Nordic UK launched to market Rabipur\u00ae<\/sup>, Vivotif\u00ae<\/sup>, Vaxchora\u00ae<\/sup> and Vimkunya\u00ae<\/sup>\u25bc chikungunya<\/span> vaccine (recombinant, adsorbed) in the UK3\u20136<\/sup><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n

\n
\n

Protecting tomorrows today\u00a0<\/strong><\/h2>\n

We\u2019re focused on and pledge our commitment to four areas:<\/p>\n

\u00a0<\/strong><\/p>\n

\n
\n

\"\"<\/p>\n

Ensuring reliable supply of vaccines<\/strong><\/p>\n<\/div>\n

\n

\"\"<\/strong><\/p>\n

Being a trusted partner<\/strong><\/p>\n<\/div>\n

\n

\"\"<\/strong><\/p>\n

Continued R&D investment<\/strong><\/p>\n<\/div>\n

\n

\"\"<\/strong><\/p>\n

Applying our innovative spirit to provide leadership in infectious diseases and travel health<\/strong><\/p>\n<\/div>\n<\/div>\n <\/div>\n<\/section>\n \n\n\n

\n
\n

Prescribing Information for our vaccines<\/h2>\n \n \n
\n \n

IMVANEX\u00ae<\/sup><\/h3>Click for IMVANEX\u00ae Prescribing information (External Link)<\/a>
<\/div><\/div><\/div><\/div><\/div>

RABIPUR\u00ae<\/sup><\/h3>Click for RABIPUR\u00ae Prescribing information (External Link)<\/a>
<\/div><\/div><\/div><\/div><\/div>

VIMKUNYA\u00ae<\/sup><\/h3>Click for Vimkunya\u00ae Prescribing information (External Link)<\/a>
<\/div><\/div><\/div><\/div><\/div>

VIVOTIF\u00ae<\/sup><\/h3>Click for VIVOTIF\u00ae Prescribing information (External Link)<\/a>
<\/div><\/div><\/div><\/div><\/div>

VAXCHORA\u00ae<\/sup><\/h3>Click for VAXCHORA\u00ae Prescribing information (External Link)<\/a>
<\/div><\/div><\/div><\/div><\/div>

Order your vaccines<\/h3>

Our vaccines are distributed in the UK by Polar Speed. To place an order, you\u2019ll need a Bavarian Nordic\/Polar Speed account. <\/h3>
<\/use><\/svg><\/span>Order your vaccines<\/a><\/div><\/div><\/div><\/div><\/div><\/div> <\/div>\n <\/div>\n<\/section>\n\n\n\n
\n
\n

Published date: 1 May 2026<\/span><\/p>\n

UK-CHIK-2600008 | May 2026<\/p>\n<\/div>\n

<\/div>\n <\/div>\n<\/section>\n\n\n
\n
\n
\n
\n

\n